Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, other studies do not show exaggerated lean mass loss with GLP-1RA treatment.37,38”
From Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies (2024) · cites this paper as [37]
In the citing paper
“Volpe et al. observed that in T2DM patients (mean age: 64.9 years) treated with subcutaneous semaglutide, reductions in the SMI were smaller than those in the fat mass index (FMI) [56], and the findings suggest a preservation of muscle strength and muscle quality.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 1×
“It is commonly linked to being overweight/obesity, metabolic syndrome, arterial hypertension, and cardiovascular (CV) and chronic renal diseases [1].”
BackgroundRoberts, H. C., Denison, H. J., Martin, H. J., Patel, H. P., Syddall, H., Cooper, C., & Sayer, A. A. (2011) · Age and Ageing · doi:10.1093/ageing/afr051 · Cited by 3,001 · cited 1×
“Three separate repeat measurements were recorded for each hand and the best value was selected for the analysis [23].”
MethodMechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867 · cited 3×
“The accumulation of VAT is a well-known risk fac- tor underlying the development of insulin resistance, T2D, and CVD [27].”
BackgroundInfluentialWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · cited 1×
“A weight loss of at least 5% of body weight from the baseline to 3 and 6 months was considered to be clinically relevant [25].”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“They reduce hyperglycemia by increasing insulin and decreasing glucagon secretion in a glucose-dependent manner, also providing significant weight loss by reducing the appetite and food consumption [4].”
BackgroundPathogenesis of insulin resistance in skeletal muscle
Abdul-Ghani, M. A., & DeFronzo, R. A. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/476279 · Cited by 670 · cited 1×
“Skeletal muscle is responsible for the uptake of around two-thirds of ingested glucose via an insulin-mediated mechanism elicited by a post-prandial glycemic excursion [10].”
BackgroundObesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance
Kojta, I., Chacińska, M., & Błachnio-Zabielska, A. (2020) · Nutrients · doi:10.3390/nu12051305 · Cited by 526
Cited by
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
“37,38 There are several potential reasons for the heterogeneity in the reported effects of GLP-1RAs on lean mass changes in clinical trials.”
Brown, T. M., Pack, Q. R., Aberegg, E., Brewer, L. C., Ford, Y. R., Forman, D. E., Gathright, E. C., Khadanga, S., Ozemek, C., Thomas, R. J., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001289 · Cited by 288
“Weight loss medications 64 and bariatric surgery 65 can help reduce body fat but may also reduce lean mass even when combined with exercise training.”
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024) · Circulation · doi:10.1161/circulationaha.124.067676 · Cited by 180
“36,37 There are several potential reasons for the heterogeneity in reported effects of GLP-1 RA on lean mass changes in clinical trials.”
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
“Real-life studies have confirmed previous findings in T2D patients with and without weight excess up to one year of treatment [183–185].”
MethodSelf-citationA systematic review of the effect of semaglutide on lean mass: insights from clinical trials
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2343092 · Cited by 97
“Contrastingly, in studies with shorter time frames, such as those by Volpe et al. [26,28], and Gibbons et al. [27], lean mass remained relatively stable despite the use of higher doses, possibly due to the limited time frame resulting in less total weight loss.”
ResultVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84
“, KG, Hamburg, Germany), as described elsewhere [28].”
BackgroundResultSelf-citationVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Self-citationPrevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 67
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Szekeres, Z., Nagy, A., Jahner, K., & Szabados, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158214 · Cited by 77
Agius, R., Pace, N. P., & Fava, S. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3725 · Cited by 74
“264 268–270 FGF21 is also being proposed as a potential novel therapeutic modality, especially with regard to improving hepatic steatosis.”
BackgroundComparison between obese and non-obese nonalcoholic fatty liver disease
Chan, W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0350 · Cited by 63
“Another study found that semaglutide resulted in significant declines in fat mass index and visceral adipose tissue, but not skeletal mass index, fat free mass index, and muscle strength.(54) However, further studies are needed on the use of these emerging novel therapies in lean or non-obese NAFLD patients.”
BackgroundThe effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
“Notably SMI stabilized after 3 months, with handgrip strength was unchanged after 6 months of treatment [52].”
Uchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., & Tanaka, Y. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4987 · Cited by 52
“Changes in BMI, whole-body fat, whole-body lean mass, Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org380 and SMI are shown in Figure 2.”
BackgroundInfluentialEffects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44
Brown, T. M., Pack, Q. R., Beregg, E. A., Brewer, L. C., Ford, Y. R., Forman, D. E., Gathright, E. C., Khadanga, S., Ozemek, C., & Thomas, R. J. (2025) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000930 · Cited by 53
“Weight loss medications 56 and bariatric surgery 57 can help reduce body fat but may also reduce lean mass even when combined with exercise training.”
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
“In the other study (37), involving subcutaneous administration of semaglutide in a population of 40 patients with a mean BMI of 38.8 kg/m2, a weight loss of 9.89kg was observed after 6 months.”
BackgroundInfluentialGlucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
Self-citationNelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & IDRIS, I. R. (2025) · Obesity Reviews · doi:10.1111/obr.13916 · Cited by 49
Luo, Z.-Y., Li, X., Chen, C.-T., Kang, H.-H., Zhang, Z., Wang, D., & Gong, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2419989 · Cited by 36
“GLP-1 RAs are demonstrated to induce weight loss, ameliorate body composition by almost entirely reducing fat mass (especially visceral fat mass), preserve fat-free mass and skeletal muscle mass, and improve liver steatosis/fibrosis [6–9].”
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
“At 6 months, semaglutide provoked an average weight loss of 10 kg predominantly due to a decline in fat mass and visceral adipose tissue and, in a small proportion, due to a reduction in skeletal muscle mass [115].”
BackgroundEffect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Prokopidis, K. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70355 · Cited by 29
Wang, S., Wang, S., Wang, Y., & Luan, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01520-3 · Cited by 27
Volpe, S., Vozza, A., Lisco, G., Fanelli, M., Racaniello, D., Bergamasco, A., Triggiani, D., Pierangeli, G., Pergola, G. D., Tortorella, C., et al. (2024) · Nutrients · doi:10.3390/nu16223841 · Cited by 27
“So far, few studies have examined in patients with T2D the relation between body composition and antihyperglycemic drugs with a proven effect on body weight, such as semaglutide [20–22].”
Self-citationStafeev, I., Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E. A., Zubkova, E., Sineokaya, M. S., Ratner, E. I., Menshikov, M. Y., Parfyonova, Y. V., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176476 · Cited by 23
Lu, J., Zou, S., Liu, X., Wong, T. Y. P., Zhang, X., Xu, K., Zhao, Y., Hong, Y., Cen, A., & Wang, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177885 · Cited by 28
Are we giving too much weight to lean mass loss?
Bolte, J., Smelter, A. A., & Norton, L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102253 · Cited by 22
Huang, Y., Liao, J., & Liu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1222636 · Cited by 19
Scavo, M. P., Lisco, G., Depalo, N., Rizzi, F. R., Volpe, S., Arrè, V., Carrieri, L., Notarnicola, M., Nunzio, V. D., Curri, M. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031493 · Cited by 19
“In patients with T2D, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to regulate blood glucose while also promoting weight loss [6,7] to provide renal and cardiovascular protection [8,9] and improve body composition [10].”
BackgroundSelf-citationSawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
CORTES, T. M., Vásquez, L., Serra, M. C., Robbins, R. N., Stepanenko, A. R., Brown, K. R., Barrus, H., Campos, A., Espinoza, S. E., & Musi, N. (2024) · JMIR Research Protocols · doi:10.2196/62667 · Cited by 21
“One study found the preservation of grip strength [14] but have not evaluated other validated measures of function in older adults such as short physical performance battery and 6-minute walk distance.”
BackgroundResultVozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Self-citationAdvances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“Similarly, Volpe et al. observed that in T2DM patients (mean age: 64.9 years) treated with subcutaneous semaglutide, reductions in the SMI were smaller than those in the fat mass index (FMI) [56], and the findings suggest a preservation of muscle strength and muscle quality.”
InfluentialMuscle health in the modern era of incretin‐based therapies
Girolamo, G. D., Sangineto, M., Gioia, G. D., Bianco, R., Ciarnelli, M., & Serviddio, G. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70155 · Cited by 16
“36 In a single-arm trial in people with HIV and MASLD, 24 weeks of semaglutide reduced psoas muscle volume ( ~ 9”
Wen, J., How-Volkman, C., Truong, A., Nadora, D., Bernstein, E. M., Akhtar, M., Puglisi, J. L., & Frezza, E. E. (2024) · Cureus · doi:10.7759/cureus.75304 · Cited by 12
Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study
Tao, M., Zhou, G., Liu, J., He, M., Luo, X., Wang, C., & Zhang, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111586 · Cited by 8
Mateos, I. C., Morales, C., & Aguilera, B. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155434 · Cited by 12
“These findings are in accordance with prior real-world observational studies evaluating the effects of once-weekly semaglutide on body composition in T2D patients, despite being limited to a six-month follow-up [35,37,40].”
InfluentialKatsarou, A., Kouvari, M., Hill, M. A., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155714 · Cited by 8
Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety
de Lucas, M. D. G., Perez-Belmonte, L. M., Avilés, B., Jiménez-Millán, A., Rivas‐Ruiz, F., & Miramontes‐González, J. P. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.03985-4 · Cited by 8
Nalbandian, M., Lone, J. B., Moal, E. L., Kim, I., Jeuris, K., Li, Y. K., Kraft, P. E., Zhao, M., Koleckar, K., Zhang, Z., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606533123 · Cited by 10
“In mice, some studies report impaired muscle function using forelimb grip strength (45), or ex vivo twitch force (30), whereas other clinical studies report little to no change in physical performance or strength assessed by hand grip strength (48) or by chair rise and gait speed (31).”
The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients
Vogel, A. S., Roediger, R., Ahrens, D. V., Fortune, B. E., Schwartz, J. M., Frager, S. Z., Chacko, K. R., & Tow, C. (2024) · Life · doi:10.3390/life14060685 · Cited by 6
“While there are concerns surrounding a reduction in lean body mass with the use of these agents, in two recent trials, once weekly semaglutide was shown to lead to weight loss without significant effects on skeletal muscle mass [79,80].”
BackgroundBusk‐Cirera, L., Carlsen, I. Ø., Madsen, L. B., Sandsdal, R. M., Jensen, E., Jensen, S. B. K., & Torekov, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71006 · Cited by 6
Adverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Body Composition Changes with Semaglutide: A Systematic Review and Meta-AnalysisPreprint
Giorelli, G., Mizumoto, M., Sartoretto, S., Giorelli, S., Giorelli, P., Bedin-Pochini, A., Toledo, D. O., Barreto, G., & Saunders, B. (2025) · medRxiv · doi:10.1101/2025.09.29.25336760 · Cited by 2
Sen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Recent Articles—Skeletal Muscle and Other Topics in Diabetes
Bloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70169 · Cited by 1
“Both tirzepatide [16] and semaglutide [17] are associated with improved muscle function, and administration of liraglutide along with resistance training is associated with increased lean mass along with weight loss [18].”
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
Self-citationSancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Venza, M., & Venza, I. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-05980-3 · Cited by 2
“…(BIA) and related methods provide a more nuanced picture: • A 26-week prospective study” in type 2 diabetes patients showed that semaglutide significantly reduced body weight and fat mass, with a smaller but measurable loss of fat-free mass; the relative proportion of lean mass increased [15].”
Alshahrani, O. A. S., & Almalki, M. S. (2024) · Cureus · doi:10.7759/cureus.65242 · Cited by 5
“A single-arm, open-label study by Volpe et al. (2022) [39] showed that the drug improved HbA1C (- 11.16±2.99; p<0.01) and caused a significant decrease in BW (-9.89±0.99 kg; p<0.01) at all observational points.”
BackgroundInfluentialNalbandian, M., Lone, J., Moal, E. L., Kim, I., Li, Y., Kraft, P., Zhao, M., Kolacar, K., Zhang, Z., Svensson, K. J., et al. (2026) · bioRxiv · doi:10.64898/2026.02.26.708119 · Cited by 1
“In mice, some studies report impaired muscle function using forelimb grip strength (50), or ex vivo twitch force (31), whereas other clinical studies report little to no change in physical performance or strength assessed by hand grip strength (53) and chair rise and gait speed (32).”
The effect of semaglutide on body weight in patients with type 2 diabetes mellitus
Demidova, T. Y., & Titova, V. V. (2024) · FOCUS Endocrinology · doi:10.15829/2713-0177-2024-5-1-04 · Cited by 3
Tomasiewicz, A., Zabierowski, J., Pachana, M., Kukuła, P., Piersiak, M., Sawczuk, H., Marschollek, J., & Ziomek, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4067
Faheem, M. S. B., Cheema, S., Anwar, A., Rafay-ur-Rehman, M., Farhan, K., Mazhar, I., Shahid, H., Khan, F. U., Faheem, M. S. B., Usman, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9176897/v1
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Biryukova, E. V., & Викторович, Ш. М. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-103
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
“One study found that changes in muscle quality (defined by calculating hand grip strength divided by skeletal muscle mass) were not significant[44], and another reported that changes in muscle fat content were not significant [41].”
InfluentialWolszczak, A., Martynowska, W., Hajt, M., Misiaszek, D., Graczyk, A., Ciecierski, P., Grabowska, N., Motor, J., & Turzyńska, P. P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5940
Sukurica, E., Sengul, G. F., & Uysal, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71422 · Cited by 2
Functional Implications of GLP-1RA Use Beyond Obesity in Aging Adults
Mascone, S. E., Prior, S. J., & Addison, O. R. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00467-0
“The majority of prior studies have found that handgrip strength was maintained versus baseline values with 6–12 months of GLP-1RA usage [24–26], though one study observed a decrease in handgrip strength [27] after 24 months of GLP-1RA usage.”
Machado, L. G., Schmidt, P. H. S., Petroski, G. T., Costa, G. L. L., Ribeiro, L., da Cruz, J. V. R., Canto, G. D. L., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71432 · Cited by 2
Metadata
- Authors
- Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., & Piazzolla, G.
- Affiliations
- University of Bari Aldo Moro (IT)
- Unit of Internal Medicine and Geriatrics, National Institute of Gastroenterology IRCCS “Saverio de Bellis” Research Hospital, Castellana Grotte, Via Turi 27, 70013 Bari, Italy
- Corresponding author
- Piazzolla, Giuseppina
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-06-10
- Volume
- 14
- Issue
- 12
- Pages
- 2414
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9227575
- OpenAlex
- W4282558207
- Cited by
- 67
- References
- 36
- Citations by year
- 2026: 17 · 2025: 15 · 2024: 23 · 2023: 10 · 2022: 2
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, body composition, weight loss, GLP-1 receptor agonists, visceral adipose tissue, fat mass index, fat-free mass index, skeletal muscle mass, muscle strength, HbA1c, bioelectrical impedance analysis, ultrasonography
- MeSH terms
- Semaglutide, Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.